|
KMID : 0380020040190010083
|
|
Korean Journal of Biotechnology and Bioengineering
2004 Volume.19 No. 1 p.83 ~ p.87
|
|
|
Effect and Safety of Replacement Therapy for PMS (Post-/Premenopausal Syndrome)
|
|
Lee Duck-Joo
Hong Uk-Ki
Kim Jae-Soo
Cho Han-Sung
Han In-Kwon
|
|
|
Abstract
|
|
|
|
This research was designed to investigate the effects of Estromon including FGF271 (Female Growth Factor 271) which was developed as a phytoestrogen for post- and pre-menopausal syndrome (PMS). The oral administration of two capsules of Estromon twice a day for 3 months significantly improved PMS (Post-/Premenopausal Syndrome) about 5 times more than placebo group (OR=5.04, 95% C.1. 1.40-18.14). In the group of 24 patients having taken Estromon, the concentration of alkaline phosphatase asn the bone marker decreased by -9.39.5 IU/L after 3 months with a statistic significance. Since the concentration of osteocalcin as the other bone marker also decreased in more patients in Estromon group than in placebo group, the bone density might be expected to be improved in long-term treatment. Serum human growth hormone level increased in 17 out of 24 patients. Triglycerides decreased by -8.040 (mg%) after 1 month and by -4.436 (mg%) after 3 months in Estomon group while triglycerides increased in both cases in placebo group (p.0.01). Therefore, PMS patients might benefit from Estromon as a phytoestrogen supplement without any serious side effects.
|
|
|
KEYWORD
|
|
|
PMS, phytoestrogen, FGF271, estromon
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|